Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up of Glecaprevir/Pibrentasvir in Chronic HCV
NCT02441283Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2015
- Primary completion
- Oct 2019
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 3 trial of glecaprevir, pibrentasvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Jun 2015; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02441283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441283.